Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -167.64% is 76% below its 5-year average of -95.34%, near the low end of its 5-year range (-194.99%–-37.09%).
8.87% above its 12-month average of -183.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -38.24%.
RETURN ON ASSETS (ROA)
-167.64%
RETURN ON ASSETS (ROA) AVG TTM
-183.95%
RETURN ON ASSETS (ROA) AVG 3Y
-119.46%
RETURN ON ASSETS (ROA) AVG 5Y
-95.34%
RETURN ON ASSETS (ROA) AVG 10Y
-102.65%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.87%
CURRENT VS 3Y AVG
-40.33%
CURRENT VS 5Y AVG
-75.84%
CURRENT VS 10Y AVG
-63.32%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-419.98%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$109.14M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$110.30M
Return on Assets (ROA)
-85.80%
TTM Avg
-37.85%
3Y Avg
-56.27%
5Y Avg
-56.27%
Market Cap
$107.17M
Return on Assets (ROA)
-14.14%
TTM Avg
-26.48%
3Y Avg
-30.34%
5Y Avg
-26.58%
Market Cap
$107.09M
Return on Assets (ROA)
-80.25%
TTM Avg
-36.24%
3Y Avg
-78.62%
5Y Avg
-77.58%
Market Cap
$106.98M
Return on Assets (ROA)
-16.87%
TTM Avg
-6.13%
3Y Avg
-6.48%
5Y Avg
-5.59%
Market Cap
$106.96M
Return on Assets (ROA)
-233.43%
TTM Avg
-298.69%
3Y Avg
-252.88%
5Y Avg
-237.20%
Market Cap
$106.93M
Return on Assets (ROA)
-63.19%
TTM Avg
-62.03%
3Y Avg
-51.81%
5Y Avg
-103.22%
Market Cap
$106.52M
Return on Assets (ROA)
-70.09%
TTM Avg
-324.97%
3Y Avg
-229.15%
5Y Avg
-168.27%
Market Cap
$112.57M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $109.14M | -167.64% | -183.95% | -119.46% | -95.34% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | -85.80% | -37.85% | -56.27% | -56.27% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | -14.14% | -26.48% | -30.34% | -26.58% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | -80.25% | -36.24% | -78.62% | -77.58% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | -16.87% | -6.13% | -6.48% | -5.59% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -233.43% | -298.69% | -252.88% | -237.20% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | -63.19% | -62.03% | -51.81% | -103.22% |
| Immunic, Inc. (IMUX)vs › | $106.52M | -70.09% | -324.97% | -229.15% | -168.27% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -72.42% | -66.03% | -45.57% | -48.77% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | -48.90% | -85.01% | -256.52% | -384.82% |
ROA
-167.6%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -194.99% |
| 2024-12-31 | -172.92% |
| 2023-12-31 | -37.09% |
| 2022-12-31 | -72.84% |
| 2021-12-31 | -40.17% |
| 2020-12-31 | -54.01% |
| 2019-12-31 | -56.02% |
| 2018-12-31 | -165.52% |
| 2017-12-31 | -189.65% |
| 2016-12-31 | -77.30% |
| 2015-12-31 | -68.61% |
| 2014-12-31 | -78.45% |
| 2013-12-31 | -42.17% |
